These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 18061446)
21. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Kitano Y; Suzuki T; Kawahara E; Yamazaki T Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510 [TBL] [Abstract][Full Text] [Related]
22. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. Wagner J; von Matt P; Sedrani R; Albert R; Cooke N; Ehrhardt C; Geiser M; Rummel G; Stark W; Strauss A; Cowan-Jacob SW; Beerli C; Weckbecker G; Evenou JP; Zenke G; Cottens S J Med Chem; 2009 Oct; 52(20):6193-6. PubMed ID: 19827831 [TBL] [Abstract][Full Text] [Related]
23. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347 [TBL] [Abstract][Full Text] [Related]
24. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Chen FL; Xia W; Spector NL Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964 [TBL] [Abstract][Full Text] [Related]
26. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637 [TBL] [Abstract][Full Text] [Related]
27. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). Liu L; Siegmund A; Xi N; Kaplan-Lefko P; Rex K; Chen A; Lin J; Moriguchi J; Berry L; Huang L; Teffera Y; Yang Y; Zhang Y; Bellon SF; Lee M; Shimanovich R; Bak A; Dominguez C; Norman MH; Harmange JC; Dussault I; Kim TS J Med Chem; 2008 Jul; 51(13):3688-91. PubMed ID: 18553959 [TBL] [Abstract][Full Text] [Related]
28. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388 [TBL] [Abstract][Full Text] [Related]
29. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Cai ZW; Wei D; Schroeder GM; Cornelius LA; Kim K; Chen XT; Schmidt RJ; Williams DK; Tokarski JS; An Y; Sack JS; Manne V; Kamath A; Zhang Y; Marathe P; Hunt JT; Lombardo LJ; Fargnoli J; Borzilleri RM Bioorg Med Chem Lett; 2008 Jun; 18(11):3224-9. PubMed ID: 18479916 [TBL] [Abstract][Full Text] [Related]
30. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858 [TBL] [Abstract][Full Text] [Related]
31. Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors. Bardelle C; Barlaam B; Brooks N; Coleman T; Cross D; Ducray R; Green I; Brempt CL; Olivier A; Read J Bioorg Med Chem Lett; 2010 Nov; 20(21):6242-5. PubMed ID: 20850301 [TBL] [Abstract][Full Text] [Related]
32. Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2) with osteogenic activity in osteoblast cells. Allen JG; Lee MR; Han CY; Scherrer J; Flynn S; Boucher C; Zhao H; O'Connor AB; Roveto P; Bauer D; Graceffa R; Richards WG; Babij P Bioorg Med Chem Lett; 2009 Sep; 19(17):4924-8. PubMed ID: 19648005 [TBL] [Abstract][Full Text] [Related]
33. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. Newton R; Bowler KA; Burns EM; Chapman PJ; Fairweather EE; Fritzl SJR; Goldberg KM; Hamilton NM; Holt SV; Hopkins GV; Jones SD; Jordan AM; Lyons AJ; Nikki March H; McDonald NQ; Maguire LA; Mould DP; Purkiss AG; Small HF; Stowell AIJ; Thomson GJ; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ Eur J Med Chem; 2016 Apr; 112():20-32. PubMed ID: 26874741 [TBL] [Abstract][Full Text] [Related]
34. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606 [TBL] [Abstract][Full Text] [Related]
35. Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors. Fairhurst RA; Gerspacher M; Imbach-Weese P; Mah R; Caravatti G; Furet P; Fritsch C; Schnell C; Blanz J; Blasco F; Desrayaud S; Guthy DA; Knapp M; Arz D; Wirth J; Roehn-Carnemolla E; Luu VH Bioorg Med Chem Lett; 2015 Sep; 25(17):3575-81. PubMed ID: 26199119 [TBL] [Abstract][Full Text] [Related]
36. Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety. Li YL; Shi E; Burns D; Li Y; Covington MB; Pan M; Scherle P; Friedman S; Metcalf B; Yao W Bioorg Med Chem Lett; 2009 Sep; 19(17):5037-42. PubMed ID: 19635666 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and photophysical properties of a fluorescent cyanoquinoline probe for profiling ERBB2 kinase inhibitor response. Lee H; Landgraf R; Wilson JN Bioorg Med Chem; 2017 Nov; 25(21):6016-6023. PubMed ID: 28974323 [TBL] [Abstract][Full Text] [Related]
38. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Pissot-Soldermann C; Gerspacher M; Furet P; Gaul C; Holzer P; McCarthy C; Radimerski T; Regnier CH; Baffert F; Drueckes P; Tavares GA; Vangrevelinghe E; Blasco F; Ottaviani G; Ossola F; Scesa J; Reetz J Bioorg Med Chem Lett; 2010 Apr; 20(8):2609-13. PubMed ID: 20231096 [TBL] [Abstract][Full Text] [Related]
39. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase. Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047 [TBL] [Abstract][Full Text] [Related]